Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126653 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder, sponsored by Aardvark Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06126653 is a Phase 2 study of Autism Spectrum Disorder that has completed, run by Aardvark Therapeutics. The registered enrollment target is 5 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06126653, a Phase 2 study of Autism Spectrum Disorder, has completed, sponsored by Aardvark Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low Dose ARD-501
- DRUG High Dose ARD-501
Study Locations (1)
Nevada
- Center for Psychiatry and Behavioral Medicine Inc - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2025-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06126653
The ClinicalTrials.gov registry entry for NCT06126653 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (96% lower). The listed sponsor is Aardvark Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06126653 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.
Frequently Asked Questions
What is clinical trial NCT06126653 about?
NCT06126653 is a clinical study titled "A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder". This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.
What is the current status of trial NCT06126653?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2024-08-01. Estimated completion is 2025-01-13.
What conditions does trial NCT06126653 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT06126653?
The interventions under investigation include: Placebo (DRUG), Low Dose ARD-501 (DRUG), High Dose ARD-501 (DRUG).
Who is sponsoring clinical trial NCT06126653?
This trial is sponsored by Aardvark Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06126653 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.